DEF: Solana Co. Seeks Shareholder Approval for Crypto Warrants, Equity Plan, New Director
Proxy Statement
Solana Company calls a special meeting to approve significant share issuances for crypto-related warrants, expand its equity incentive plan, and elect a new director amidst a strategic pivot to digital assets.
Summary
- A Special Meeting of Stockholders is scheduled for October 30, 2025, to vote on five key proposals.
- Shareholders will vote on electing Cosmo Jiang as a new director to the Board of Directors.
- Approval is sought for the issuance of up to 11,091,178 shares of common stock upon the exercise of Strategic Advisor Warrants issued to Pantera Capital Management LP and Summer Wisdom Holdings Limited.
- Shareholders will also vote on approving the issuance of shares for 10,994,199 Cryptocurrency Pre-Funded Warrants and 10,994,199 Cryptocurrency Stapled Warrants, issued in connection with a private placement offering that accepted Solana (SOL) cryptocurrency as consideration.
- An amendment to the 2022 Equity Incentive Plan is proposed to increase the number of shares available for issuance thereunder by 4,000,000 shares, which is also necessary for certain restricted stock units granted to Executive Chairman Joseph Chee.
- The Board of Directors unanimously recommends voting FOR all proposals.
- The company reported net losses of $(11.7) million in 2024, $(8.9) million in 2023, and $(14.1) million in 2022.
- A $100 investment in the company resulted in a Total Shareholder Return of $0.10 in 2024, $1.22 in 2023, and $2.33 in 2022, indicating significant value erosion.
- Executive officers received one-time discretionary cash bonuses totaling $890,000 for CEO Dane C. Andreeff and $610,000 for CFO Jeffrey S. Mathiesen, which offset future severance benefits.
Sentiment
Score: 3
Explanation: The company is undergoing a significant strategic pivot into the digital asset space, which is inherently high-risk and high-reward. However, the historical financial performance (consistent net losses and abysmal Total Shareholder Return) is extremely poor. The proposed dilution from warrant exercises and equity plan expansion is substantial. While the new board member and strategic advisors bring relevant expertise for the new direction, the current financial state and the nature of executive compensation (large bonuses despite poor performance, and payments to avoid change-in-control triggers) raise significant concerns about shareholder alignment and value protection.
Positives
- The nomination of Cosmo Jiang, a General Partner at Pantera Capital and founder of Nova River Management, brings significant expertise in digital assets and technology-focused investment strategies to the Board of Directors.
- The company's strategic pivot into the blockchain and digital asset industry, including the acceptance of Solana (SOL) cryptocurrency in a private placement, positions it in a high-growth sector.
- The adoption of a Policy for the Recovery of Erroneously Awarded Compensation (clawback policy) aligns with Nasdaq listing standards and enhances corporate governance.
- The separation of the Chair of the Board and Chief Executive Officer roles is intended to provide strong leadership and oversight.
Negatives
- The company has incurred substantial net losses, reporting $(11.7) million in 2024, $(8.9) million in 2023, and $(14.1) million in 2022.
- Total Shareholder Return (TSR) has been extremely poor, with a $100 initial investment yielding only $0.10 in 2024, $1.22 in 2023, and $2.33 in 2022, indicating significant shareholder value destruction.
- The proposed issuance of up to 11,091,178 shares for Strategic Advisor Warrants and 21,988,398 shares for Cryptocurrency Warrants, plus an additional 4,000,000 shares for the equity incentive plan, represents substantial potential dilution for existing shareholders.
- Executive Chairman Joseph Chee and new director nominee Cosmo Jiang are deemed non-independent, raising potential corporate governance concerns, especially given Mr. Chee's entity (Summer Wisdom Holdings Limited) is a recipient of Strategic Advisor Warrants and Restricted Stock Units (RSUs).
- One-time discretionary cash bonuses of $890,000 for the CEO and $610,000 for the CFO were paid, which, despite offsetting future severance, are significant payouts given the company's poor financial performance and shareholder returns.
Risks
- Failure to obtain stockholder approval for Proposals 1, 2, 3, or 4 could lead to the inability to elect the new director, render Strategic Advisor Warrants and Cryptocurrency Warrants unexercisable, and prevent the expansion of the equity incentive plan, potentially hindering strategic initiatives and executive compensation.
- If the equity incentive plan amendment is not approved, the company may need to increase cash compensation, which could deplete cash reserves and may not align employee interests with stockholders as effectively as equity.
- The company's compensation practices and policies are subject to review for potential material adverse effects on the company.
- Certain payments or vesting accelerations upon a change in control could be subject to non-deductibility for the company and a 20% excise tax for participants under Code Section 280G.
- Non-compliance with Code Section 409A for deferred compensation plans could result in current income inclusion, interest, and an additional 20% tax for participants.
Future Outlook
The company adopted and implemented a Solana treasury strategy in September 2025, indicating a significant strategic pivot towards digital assets. It aims to attract and retain employees, consultants, officers, and non-employee directors through equity compensation to contribute to long-term performance and growth. The Board believes the new director's expertise will enhance oversight and support long-term growth in the blockchain and digital asset industry.
Management Comments
- "Thank you for your continued support of Solana Company (f/k/a Helius Medical Technologies)." Dane C. Andreeff, President and CEO.
- The Board unanimously recommends voting FOR the election of each director nominee and FOR Proposals 2, 3, 4 and 5.
- The Board believes that, by separating the positions of Chair of the Board and Chief Executive Officer, the Board can provide significant leadership to management and strong oversight of key opportunities and risks impacting the Company.
- The Board believes that Mr. Jiang will be a strong addition due to his extensive experience in financial services and digital assets, and his investment and industry expertise will enhance the Board's oversight and support the Company's long-term growth.
- The Compensation Committee has not previously used or considered Compensation Actually Paid (CAP) as computed in accordance with Item 402(v) of Regulation S-K to set target compensation amounts or align NEO compensation to Company performance.
Industry Context
The company's name change to 'Solana Company' and the acceptance of Solana (SOL) cryptocurrency as consideration, along with the engagement of strategic advisors in the 'crypto technology sector' and the 'digital asset treasury' strategy, indicate a significant pivot into the blockchain and digital asset industry. This is a highly competitive and volatile sector. The appointment of Cosmo Jiang, a General Partner at Pantera Capital, and Joseph Chee's affiliations with blockchain-focused investment entities further reinforce this strategic direction, moving away from its previous medical technology focus.
Comparison to Industry Standards
- The filing does not provide specific comparable companies or projects for direct industry comparison.
- The company's Total Shareholder Return (TSR) of $0.10 for a $100 investment in 2024, $1.22 in 2023, and $2.33 in 2022 is significantly below typical industry benchmarks, indicating severe underperformance.
- Consistent net losses of $(11.7) million in 2024, $(8.9) million in 2023, and $(14.1) million in 2022 suggest financial performance well below that of healthy or growing companies in any sector.
- Executive compensation, including substantial one-time cash bonuses to the CEO ($890,000) and CFO ($610,000) despite poor financial results and shareholder value destruction, appears misaligned with best practices for performance-based compensation in most industries.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | N/A | Cosmo Jiang | Upon shareholder approval (October 30, 2025 Special Meeting) | Nominated for election to the Board of Directors to bring expertise in digital assets and technology-focused investment strategies. |
| Director | Jeffrey S. Mathiesen | N/A (resigning) | Upon shareholder approval of Cosmo Jiang's election | Will resign from the Board upon the election and qualification of the new director nominee. |
| Executive Chairman | N/A | Joseph Chee | September 2025 | Appointed Executive Chairman following the closing of recent offerings, bringing experience in fintech, blockchain, and healthcare investments. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Independence Determination | The Board determined that new director nominee Cosmo Jiang is not independent. Executive Chairman Joseph Chee is also not independent. | October 14, 2025 | Raises potential concerns regarding board oversight and decision-making impartiality, especially given related-party transactions. |
| Policy Adoption | Adopted a new Policy for the Recovery of Erroneously Awarded Compensation (clawback policy) as required by Nasdaq listing standards. | October 2, 2023 (for compensation received on or after) | Enhances accountability for Section 16 officers and aligns with best practices in corporate governance, mitigating risks associated with financial restatements. |
| Board Leadership Structure | The Board maintains a separation of the Chair of the Board and Chief Executive Officer positions. | Ongoing | Intended to provide significant leadership to management and strong oversight of key opportunities and risks. |
| Insider Trading Policy Update | Insider Trading Compliance Policy prohibits hedging or monetization transactions for directors and executive officers and implements quarterly trading blackout periods and pre-clearance requirements. | Ongoing | Designed to prevent insider trading and promote compliance with securities laws, enhancing market integrity and investor confidence. |
Related Party Transactions
- The company entered into a Strategic Advisor Agreement with Pantera Capital Management LP and Summer Wisdom Holdings Limited (an entity controlled by Executive Chairman Joseph Chee).
- Strategic Advisor Warrants were issued to Pantera Capital Management LP and Summer Wisdom Holdings Limited, which, upon exercise, will result in the issuance of up to 11,091,178 shares of common stock.
- Executive Chairman Joseph Chee received an equity award of 1,109,118 Restricted Stock Units (RSUs) and is eligible for additional RSUs, contingent on stockholder approval of the 2022 Equity Incentive Plan amendment.
- The company provides indemnification agreements for its directors and officers.
Stakeholder Impact
- Shareholders face significant potential dilution from the proposed issuance of up to 11,091,178 shares for Strategic Advisor Warrants, 21,988,398 shares for Cryptocurrency Warrants, and an additional 4,000,000 shares for the equity incentive plan.
- Investment professionals and regulatory authorities may scrutinize the company's corporate governance, particularly the non-independent status of key board members and the executive compensation structure amidst poor financial performance.
- Employees and consultants are targeted beneficiaries of the expanded equity incentive plan, which aims to attract and retain talent, potentially aligning their interests with long-term company performance.
- Strategic advisors (Pantera Capital and Summer Wisdom Holdings Limited) stand to gain substantial equity through warrant exercises, aligning their interests with the company's new digital asset strategy.
Next Steps
- Hold a Special Meeting of Stockholders on October 30, 2025, to vote on the proposed election of a new director, warrant issuances, equity plan amendment, and potential meeting adjournment.
- If approved, Cosmo Jiang will be elected as a new director.
- If approved, shares underlying Strategic Advisor Warrants and Cryptocurrency Warrants will become exercisable.
- If approved, the 2022 Equity Incentive Plan will be amended to increase available shares by 4,000,000, and Joseph Chee's RSU awards will become payable.
- Publish final voting results in a current report on Form 8-K within four business days of the Special Meeting.
Key Dates
| Date | Description |
|---|---|
| 2022-05-23 | 2022 Equity Incentive Plan approved by stockholders. |
| 2023-10-02 | Effective date for compensation subject to the Policy for the Recovery of Erroneously Awarded Compensation. |
| 2024-02-20 | Board approved a 4% increase to executive officers' base salaries for 2024. |
| 2024-03-01 | Compensation Committee recommended and Board approved performance targets for fiscal 2024 bonuses. |
| 2024-07-02 | Board approved grant of stock options to executive officers. |
| 2025-02-01 | Compensation Committee determined 83% of 2024 performance targets met and approved bonus payments. |
| 2025-05-23 | Amendment 2 to 2022 Equity Incentive Plan approved by stockholders, resulting in an automatic increase in shares. |
| 2025-09-15 | Company entered into Strategic Advisor Agreement with Pantera Capital Management LP and Summer Wisdom Holdings Limited. |
| 2025-09-15 | Company entered into Cryptocurrency Securities Purchase Agreements for a private placement offering. |
| 2025-09-18 | Offerings consummated; Joseph Chee entered into an executive chairman agreement. |
| 2025-09-24 | Company entered into side letter agreements with CEO Dane C. Andreeff and CFO Jeffrey S. Mathiesen for one-time cash bonuses. |
| 2025-09-25 | Board approved Amendment 3 to the 2022 Equity Incentive Plan, subject to stockholder approval. |
| 2025-09-26 | Record date for stockholders entitled to vote at the Special Meeting. |
| 2025-10-01 | Date for security ownership information presented in the filing. |
| 2025-10-14 | Date of the proxy statement and expected first mailing to stockholders. |
| 2025-10-29 | Deadline for internet and phone proxy voting (11:59 p.m. Eastern Time). |
| 2025-10-30 | Special Meeting of Stockholders at 10:00 a.m. Eastern Time. |
| 2025-11-25 | Deadline for stockholder proposals for the 2026 annual meeting (Rule 14a-8). |
| 2025-12-22 | Beginning of window for stockholder director nominations or other business for 2026 annual meeting (not Rule 14a-8). |
| 2026-01-21 | End of window for stockholder director nominations or other business for 2026 annual meeting (not Rule 14a-8). |
| 2032-02-16 | Last date for awards to be made under the 2022 Equity Incentive Plan. |
Recommendation
strong sellThe company has demonstrated extremely poor financial performance with consistent net losses and a near-total destruction of shareholder value as evidenced by the Total Shareholder Return. The proposed actions, while aiming for a strategic pivot into the volatile digital asset space, involve substantial dilution through warrant exercises and an expanded equity incentive plan. Furthermore, the large one-time cash bonuses to executives, seemingly to mitigate larger change-in-control payouts, raise serious questions about management's alignment with shareholder interests given the company's abysmal performance. The lack of independence for key board members (Mr. Jiang and Mr. Chee) and the significant related-party transactions further compound governance concerns. Investors should consider divesting given the high risk, poor historical performance, and significant dilution.
Keywords
Solana Company, proxy statement, special meeting, director election, equity incentive plan, stock options, warrants, cryptocurrency, SOL, Pantera Capital, Summer Wisdom Holdings, corporate governance, executive compensation, shareholder dilution, financial performance, net loss, Total Shareholder Return, Nasdaq Listing Rule 5635(a), related party transactions, Helius Medical Technologies
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.